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Persistent polyclonal B-cell lymphocytosis (PPBL) is rare and intriguing hematological disorder predominantly
reported in young to middle- aged smoking women. It is characterized by persistent moderate polyclonal B-cell
lymphocytosis with circulating hallmark binucleated lymphocytes and elevated polyclonal serum IgM. Most patients
have benign clinical course on long-term follow-up. Some pathologic features of PPBL may resemble malignant
lymphoma, including morphology as well as frequent cytogenetic and molecular abnormalities. Significant
symptomatic splenomegaly requiring splenectomy is very unusual for this disorder; therefore there is a lack of
descriptions of the morphologic features of the spleen in the literature. We present here one of the first detailed
descriptions of the morphologic and immunohistochemical features of the spleen from a young female with PPBL
who developed massive splenomegaly during 6-year follow up. Splenectomy was performed for symptomatic relief
and suspicion of malignant process. The morphological and immunohistochemical features of the spleen closely
mimicked involvement by B-cell lymphoma, however there was no monotypic surface light chain restriction seen
by flow cytometry and no clonal rearrangement of IgH gene was detected by molecular analysis. Evaluating a
splenectomy sample in cases like this may present a diagnostic challenge to pathologists. Therefore, correlation
with B cell clonality studies (by flow cytometry and molecular analysis), clinical findings and peripheral blood
morphology searching for characteristic binucleated lymphocytes is essential to avoid misdiagnosing this benign
process as B-cell lymphoma. We also present here a literature review on pathogenesis of PPBL.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5329558967545656
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Persistent polyclonal B-cell lymphocytosis (PPBL) is a
rare clinically benign lymphoproliferative disorder first
described by Gordon et al. in 1982 [1]. To date, around
200 cases worldwide have been reported in literature.
PPBL is characterized by chronic mild-to-moderate per-
ipheral polyclonal lymphocytosis of B cell origin as evi-
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distribution, and reproduction in any mediumatypical binucleated lymphocytes present on peripheral
blood film. The total lymphocyte count is not always
elevated in all patients. Due to the hallmark presence of
binucleated lymphocytes, this entity is also called B-cell
lymphocytosis with binucleated lymphocytes. The ma-
jority of patients also demonstrate polyclonal increase
in serum IgM. It is most frequently reported in young
or middle-aged female smokers [1-6]. Most patients
present with mild nonspecific symptoms, such as weak-
ness and fatigue. Mild splenomegaly is a single most fre-
quently reported clinical finding, present in about 10%
of patients according to the largest case series [2].
Massive splenomegaly has been only rarely reported inCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 List of antibodies/ probes
Antibody/ probe Source Dilution
CD5 (SP19) Cell Marque Co., Predilute
CD10 (56C6) Cell Marque Co., Predilute
CD20 (L26) Ventana, Arizona, USA Predilute
CD23 (1B12) Cell Marque Co. Predilute
CD43 (L60) Ventana, Arizona, USA Predilute
Cyclin D1(SP4) Medicorp, Montreal, Canada 1;50
BCL-2 (124) DAKO, Mississauga, Canada 1:40
Kappa DAKO, Mississauga, Canada 1:20,000
Lambda DAKO, Mississauga, Canada 1:20,000
EBER (RNA probe) Ventana, Arizona, USA Predilute
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course and peripheral lymphocytosis is sometimes ab-
sent, this condition is likely under-recognized. PPBL
resembles malignant lymphoproliferative disorder in
many aspects, both morphologically and at the molecu-
lar/cytogenetic levels. In addition to the hallmark atyp-
ical lymphocytes, the bone marrow of these patients
sometimes shows intrasinusoidal distribution of B lym-
phocytes resembling marrow involvement by splenic
marginal zone lymphoma [7]. We here report histo-
logical and immunohistochemical features of the spleen
in a young female with PPBL who underwent splenec-
tomy due to progressive splenomegaly on her 6th annual
follow-up. Very recently, Italian investigators Del
Giudice et al. described similar histopathological find-
ings of the spleen in three patients with PPBL and pro-
gressive splenomegaly who underwent splenectomy [8].
PPBL can be further confused with a malignant lympho-
proliferative disorder as PPBL is frequently associated
with chromosomal abnormalities and multiple BCL2/IG
gene rearrangements as seen in some lymphomas [9,10].
To avoid unnecessary aggressive treatment, it is import-
ant for pathologists to distinguish this clinically benign
disorder from malignant lymphoproliferative disorders.
Case presentation
The 38-year-old woman with a 20 years history of heavy
smoking of 1 ½ packages of cigarettes per day was referred
to QEII Health Science Centre, Halifax, Nova Scotia about
6 years ago for investigation of fatigue, frequent colds and
persistent lymphocytosis for over 6 months. Her past
medical history was unremarkable. The only positive find-
ing on her physical examination was mild splenomegaly
with spleen palpable 4 cm below left costal margin. Her
initial complete blood cell count (CBC) showed isolated
lymphocytosis of 10.2 x 109/L with peripheral blood
smears showing few atypical binucleated lymphocytes.
Flow cytometry of her peripheral blood revealed an in-
crease in polytypic CD19+/ CD20+/ CD5-/ CD10- B cells.
Serum protein electrophoresis showed elevated polyclonal
IgM at 9.6 g/L. The patient was diagnosed with PPBL and
was closely monitored by her family physician and local
oncologist. Over the following 6 years, she received no
medical intervention. Several months prior to her splenec-
tomy, she started complaining of increasing abdominal
discomfort. Her spleen slowly increased in size and
reached over 8 cm below left costal margin. She had no
hepatomegaly or lymphadenopathy on CT imaging of the
neck, chest, abdomen and pelvis. Her CBC remained un-
changed with persistent peripheral lymphocytosis varying
between 10 to 13 x 109/L and showing variable numbers
of characteristic binucleated lymphocytes. Repeated flow
cytometry of peripheral blood just prior to splenectomy
showed persistent increase in polytypic B cells. Shesubsequently underwent splenectomy for symptomatic re-
lief as well as for suspicion of “malignant transformation”.
Patient’s postoperative course was unremarkable requiring
no further therapy. The patient continued heavy smoking
throughout her years of follow-up.
Materials and methods
Histology and immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
stained with hematoxylin and eosin (H&E) and Periodic
Acid-Schiff (PAS). Immunohistochemistry was performed
on 4-μm-thick sections prepared from formalin-fixed,
paraffin-embedded tissue using an automated immunos-
tainer (Bechmark XT, Ventana Medical Systems Inc., Tuc-
son, AZ). The antigenic determinants and probes tested
are listed in table 1.
Immunophenotyping by flow cytometry
Mononuclear cells from fresh peripheral blood were sepa-
rated by density-gradient centrifugation and were charac-
terized using four-color immunostaining by a FACSCalibur
flow cytometer (Becton, Dickinson and Company, San Jose,
CA) and Cell Quest software (Becton, Dickinson and
Company, San Jose, CA). The following monoclonal anti-
bodies were used: CD45-allophycocyanin (APC), CD5-
phycoerythrin (PE), CD19-peridinin cholorophyll protein
(PerCP), CD20-fluorescin isothiocyanate (FITC), CD22-
FITC, CD23-FITC, CD38-PE, CD11c-PE, CD10-PE,
FMC7-FITC, anti-kappa chain-FITC, anti-lambda chain-
PE. CD23 and FMC7 were obtained from Beckman
Coulter (Miami, FL), and the rest of the monoclonal
antibodies were purchased from Becton, Dickinson and
Company.
Molecular analysis
DNA from paraffin-embedded spleen sections was
extracted using the commercially available DNA Blood
Mini Kit (Qiagen Inc., Mississauga, ON, Canada). B cell
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primers for the variable and joining regions as described
by Reed et al. [11]. This approach is reported to detect
83% of immunoglobulin heavy chain gene rearrange-
ments. T-cell clonality was similarly assessed using PCR-
based method for T-cell receptor γ gene rearrangement
described by Diss et al. [12]. Two reactions with primers
VgI and VgIII/IV and Jg1/2 are reported to detect 80% of
T-cell gamma gene rearrangements. A nested PCR was
also used to detect BCL2/IG gene rearrangement target-
ing the usual breakpoint regions of the t(14;18).
Results
Grossly, the spleen was enlarged, weighing 519 grams and
measuring 16 x 11 x 6.5 cm. The splenic capsule was well
preserved. Histologically, the spleen architecture was
altered with expansion of the white pulp nodules by small
mature lymphocytes with no prominent germinal center
formations identified (Figure 1 - A, B). The white pulp
nodules in some areas demonstrated fusion but no appar-
ent or distinct marginal zones were present. There wasFigure 1 Histological features of the spleen. Images of the H&E stained
showing expansion of the white pulp nodules and significant infiltration of
atypia. Occasional binucleated lymphocytes are noted in the splenic sinusoalso a massive infiltration of red pulp by similar-appearing
small lymphocytes that were located both within the sinu-
soids and splenic cords (Figure 1 - C, D). Occasional binu-
cleated lymphocytes were noted in the splenic sinusoids
(black arrows in Figure 1 - C, D and inset). No large trans-
formed lymphoid cells were identified and plasma cells
were not prominent.
Immunohistochemical analysis demonstrated massive
amount of CD20+/ BCL-2+/ CD43+ B cells located both
within the white pulp nodules as well as within the red
pulp (CD20 and BCL-2 stains shown in Figure 2 - B and
C respectively). These B cells were negative for CD10,
CD23, CD5, and cyclin D1. Only few CD3+ T cells were
present in the red and white pulp (Figure 2 - A). Scat-
tered plasma cells were polytypic using Kappa and
Lambda light chain stains and no monotypic restriction
was identified within the B lymphocytes. No EBV was
detected using EBER in situ hybridization.
Molecular analysis on paraffin- embedded spleen sam-
ple did not demonstrate clonal rearrangements of the
immunoglobulin heavy chain genes (Figure 2 - D) orspleen sections at 20x (A), 100x (B) and 400x (C, D) magnification
the red pulp by small mature lymphocytes with minimal cytologic
ids indicated by black arrows (C, D and D inset).
Figure 2 Immunohistochemical features of the spleen. Only few scattered T lymphocytes are seen as highlighted by CD3 stain (A,
magnification 100x). Majority of lymphocytes in the white and red pulp are CD20 positive (B, magnification 100x) and BCL-2 positive (C,
magnification 200x) B cells. PCR for IgH gene rearrangement performed on spleen paraffin-embedded sections reveals polyclonal pattern with no
clonal rearrangements detected (D) (Lane 1 - no DNA; Lane 2 - patient; Lane 3 - negative control; Lane 4 - positive control).
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Discussion
PPBL is an uncommon disorder characterized by an in-
dolent and benign clinical course with persistent poly-
clonal B-cell lymphocytosis and circulating binucleated
lymphocytes as well as increased polyclonal serum IgM.
There are only rare reports of PPBL in association with
malignant lymphoma or with secondary solid cancers
[2,3,13]. Since the first description in 1982, about 200
cases have been reported in the literature.
The majority of the reports focus on the study of PPBL
pathogenesis, which remains unclear. Although most
frequently detected in smokers, PPBL is also occasionally
observed in non-smokers. The association with viral infec-
tions, such as Epstein-Barr virus, is still a matter of debate
[3,14-16]. The polyclonal B cells which are expanded in
this disorder appear to be CD27+/IgM+/IgD+memory B
cells, which may result from chronic antigenic stimulation
[4,17]. PPBL is frequently linked with HLA-DR7 haplotype[18-20]. Cases of familial PPBL and the incidence of PPBL
in monozygotic twins are suggestive of a strong genetic
predisposition [21,22]. It is reasonable to speculate that
the interaction of genetic predisposition with chronic anti-
genic stimulation may lead to the development of PPBL.
Very recently, whole genome microarray expression ana-
lysis was done in 14 PPBL patients, which demonstrated
over-expression of AP-1 transcription complex and down-
regulation of Fas-apoptotic and TGFβ pathway [5]. The
polyclonality of the lymphocyte population evidenced by
flow cytometry in this disorder is challenged by rare
reports of clonal IGHD-IGHJ immunoglobulin rearrange-
ment in patients otherwise meeting diagnostic criteria of
PPBL [6,23]. These findings suggest that polyclonal expan-
sion may be followed by the emergence of predominant
clone in rare cases.
PPBL mimics malignant lymphoma morphologically.
Variable amount of hallmark atypical lymphocytes are
invariably present in peripheral circulation. Bone mar-
row changes in the PPBL patients described earlier
demonstrate an interstitial, particularly intrasinusoidal B
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disorders especially in splenic marginal zone lymphoma
[7]. However, the intravascular or intrasinusoidal pattern
of the B cell distribution in the bone marrow is most
likely a reflection of the peripheral lymphocytosis and
the recirculating nature of the lymphocytes in this be-
nign disorder. Mild splenomegaly is the most frequently
reported physical finding, which is detected in about
10% of patients according to the largest case series [2].
Massive splenomegaly is rare among these patients. Our
PPBL patient reported here manifested slowly progres-
sive splenomegaly during six years of follow-up. Her
spleen contained massive amount of CD20+/BCL-2+ B
cells within the red and white pulp mimicking B-cell
lymphoma. In their series of 5 patients Del Giudice et al.
from Italy recently reported very similar findings to ours
in three of their five PPBL patients who developed
massive splenomegaly and underwent splenectomy [8].
The B cells present both in bone marrow and spleen
show same immunophenotype including expression of
BCL-2 [7,8]. In addition, the B cells in our patient were
also positive for CD43. CD43 expression was not studied
by Del Giudice et al. and CD43 was negative in the bone
marrow reported by Feugier et al. [7]. Although expres-
sion of CD43 by B cells is often used as a marker in
favor of a B-cell lymphoproliferative disorder, it has been
recognized that CD43 can be expressed by B cells in be-
nign conditions [24,25]. Except splenomegaly, no other
abnormal physical or radiographic findings suggestive of
malignant lymphoma transformation were detected in
our patient and the five patients reported by Del Giudice
et al. Therefore, the histological and immunophenotypic
findings observed in the spleens of these PPBL patients
are most likely a reflection of their underlying benign
PPBL process.
PPBL also mimics lymphoma at cytogenetic and mo-
lecular level. The chromosomal abnormalities are fre-
quently reported in PPBL patients. Isochromosome+ i(3q)
is the most common chromosomal abnormality and is
present in 71% of cases when using the most sensitive
fluorescence in situ hybridization (FISH) method [2].
Other less common chromosomal abnormalities include
trisomy 3, premature chromosome condensation (PCC)
and chromosome instability [2,9,10]. Among the above
mentioned chromosomal abnormalities, trisomy 3 has
been reported to be associated with marginal zone lymph-
omas (MZL) and mantle cell lymphoma (MCL) [26,27].
Cytogenetic studies on our patient using FISH were per-
formed on the peripheral blood sample collected during
one of the follow up visits and demonstrated no abnor-
malities of chromosome 3. Although not detected in our
patient, BCL2/IgH gene rearrangements as seen in follicu-
lar lymphoma have been reported in some PPBL patients
by using PCR technique [7,10,28].Conclusions
Our report adds to the extremely limited literature about
the histopathologic features of PPBL; to our knowledge
this is one of the first detailed descriptions of spleen
pathology in a patient with PPBL. Both histological and
immunohistochemical findings were misleading and
mimicked B cell lymphoma. To avoid misdiagnosing this
process as B-cell lymphoma, which may lead to unneces-
sary treatment, it is important to recognize the mislead-
ing histology and somewhat unusual phenotype, assess
clonality and to be aware of the cytogenetic and molecu-
lar abnormalities that may be associated with this intri-
guing but benign entity.
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